Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Societal CDMO, Inc. (REPH)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/23/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/14/2023 |
8-K
| Quarterly results|
Docs:
|
"Societal CDMO Reports Second Quarter 2023 Financial Results Recorded Q2 Revenue of $21.8 Million Signed Multiple New Business Agreements with New and Existing Customers Secured Schedule 1 Controlled Substance Manufacturing License from Drug Enforcement Agency; Allows Expansion into Manufacture of Psychedelic Drug Products Company to Host Webcast Today at 4:30 p.m. ET SAN DIEGO, CA, and GAINESVILLE, GA – August 14, 2023 — Societal CDMO, Inc. , a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the second quarter and six months ended June 30, 2023. “The second quarter was a highly productive period. During the quarter, we co...",
"FILLED CAPSULES ORAL LIQUIDS TABLETS OPHTHALMIC DROPPERS STERILE INJECTABLES TOPICALS" |
|
| 05/26/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/18/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Societal CDMO Reports First Quarter 2023 Financial Results Recorded Q1 Revenue of $21.5 Million Signed Multiple New Business Agreements with New and Existing Customers Granted FDA Approval for Manufacture of First Commercial Tablet Product Company to Host Webcast Today at 4:30 p.m. ET SAN DIEGO, CA, and GAINESVILLE, GA – May 10, 2023 — Societal CDMO, Inc. , a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the first quarter ended March 31, 2023. “The company’s many achievements in 2022 placed Societal in an overall stronger financial position and paved the way for growth in 2023 and beyond. In the first quarter, we contin...",
"FILLED CAPSULES ORAL LIQUIDS TABLETS OPHTHALMIC DROPPERS STERILE INJECTABLES TOPICALS" |
|
| 03/24/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/01/2023 |
8-K
| Quarterly results|
Docs:
|
"Societal CDMO Reports Fourth Quarter and Full Year 2022 Financial Results Recorded Q4 Revenue of $24.3 Million, a 9% Increase Compared to Prior Year Period Clinical Trial Materials Development Business Grew by 58% in 2022; Significantly Expanded and Diversified Customer Base Executed Multi-Step Strategy Resulting in Reduction of Debt and Strengthened Financial Position Company to Host Webcast Today at 4:30 p.m. ET SAN DIEGO, CA, and GAINESVILLE, GA – March 1, 2023 — Societal CDMO, Inc. , a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the fourth quarter and year ended December 31, 2022. “One year ago, the company outlin...",
"FILLED CAPSULES ORAL LIQUIDS TABLETS OPHTHALMIC DROPPERS STERILE INJECTABLES TOPICALS" |
|
| 01/03/2023 |
8-K
| Quarterly results |
| 12/20/2022 |
8-K
| Quarterly results |
| 12/13/2022 |
8-K
| Quarterly results |
| 12/12/2022 |
8-K
| Quarterly results |
| 11/16/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
8-K
| Quarterly results |
| 09/08/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/22/2022 |
8-K
| Quarterly results |
| 08/16/2022 |
8-K
| Quarterly results |
| 08/10/2022 |
8-K
| Quarterly results |
| 06/30/2022 |
8-K
| Quarterly results |
| 06/08/2022 |
8-K
| Quarterly results |
| 05/20/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 03/21/2022 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits ... |
| 03/01/2022 |
8-K
| Quarterly results |
| 01/24/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/14/2022 |
8-K/A
| Financial Statements and Exhibits Interactive Data|
Docs:
|
"Recro Pharma, Inc. Unaudited Pro Forma Combined Statements of Operations Nine Months Ended September 30, 2021 Recro Pre-acquisition IriSys Nine months ended September 30, 2021 Six months ended June 30, 2021 July 1 to August 12, 2021 Pro forma adjustments Pro forma combined Revenue $ 53,057 $ 6,844 $ 1,142 $ — $ 61,043 Operating expenses: Cost of sales 39,831 3,529 810 470 44,640 Selling, general and administrative 13,076 3,088 618 15,571 Amortization of intangible assets 835 - - 650 1,485 Total operating expenses 53,742 6,617 1,428 61,696 Operating income 227 91 Interest expense Gain on extinguishment of debt 3,352 866 - - 4,218 Net income $ $ 1,006 $ $ $ Loss per share: Basic $ $ Diluted Weighted average shares outstanding Basic 40,137,069 7,667,075 47,804,144 Diluted 40,137,069 7,66..." |
|
| 11/12/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 11/09/2021 |
8-K
| Quarterly results|
Docs:
|
"RECRO PHARMA, INC. AND SUBSIDIARIES Consolidated Balance Sheets Assets Current assets: Cash and cash equivalents $ 23,490 $ 23,760 Accounts receivable 13,746 9,033 Contract asset 7,314 7,330 Inventory 9,440 11,612 Prepaid expenses and other current assets 2,101 2,334 Total current assets 56,091 54,069 Property, plant and equipment, net 50,021 43,841 Operating lease asset 5,963 486 Intangible assets, net 5,993 700 Goodwill 39,568 4,319 Other assets 146 — Total assets $ 157,782 $ 103,415 Liabilities and shareholders’ equity Current liabilities: Accounts payable $ 1,916 $ 1,804 Current portion of debt — 1,474 Current portion of related party debt 2,039 — Current portion of operating lease liability 1,049 145 Accrued expenses and other current liabilities 7,856 4,380 Total current liabilities..." |
|
| 09/10/2021 |
8-K/A
| Quarterly results |
| 08/23/2021 |
8-K
| Quarterly results |
| 08/19/2021 |
8-K
| Quarterly results |
| 08/13/2021 |
8-K
| Quarterly results |
| 08/09/2021 |
8-K
| Quarterly results |
|
|
|